S.‐H.I. Ou

1.3k total citations · 1 hit paper
23 papers, 938 citations indexed

About

S.‐H.I. Ou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, S.‐H.I. Ou has authored 23 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in S.‐H.I. Ou's work include Lung Cancer Treatments and Mutations (19 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Diagnosis and Treatment (6 papers). S.‐H.I. Ou is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Diagnosis and Treatment (6 papers). S.‐H.I. Ou collaborates with scholars based in United States, South Korea and France. S.‐H.I. Ou's co-authors include Hoda Anton‐Culver, Jason A. Zell, Argyrios Ziogas, Benjamin Solomon, A. John Iafrate, Geoffrey I. Shapiro, Keith D. Wilner, Donghyeon Kim, Tiziana Usari and Stewart C. Wang and has published in prestigious journals such as Cancer, Annals of Oncology and European Journal of Cancer.

In The Last Decade

S.‐H.I. Ou

23 papers receiving 914 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

2019 365 citations A. Shaw, Yung‐Jue Bang et al. Annals of Oncology profile →

Peers

S.‐H.I. Ou

PRM

ONCOL

MB

CR

PFM

Anna Bettini Italy

Tejas Patil United States

Sehhoon Park South Korea

Sankar Srinivasan India

Mai Trong Khoa Vietnam

Lilia Stelmakh Russia

José Rodrigues Pereira Brazil

Jie‐Tao Ma China

Sayed M.S. Hashemi Netherlands

Reiko Kaji Japan

Anna Bettini Italy

S.‐H.I. Ou

574 ×0.8

PRM

580 ×1.1

ONCOL

203 ×0.7

MB

201 ×1.0

CR

95 ×1.2

PFM

Citations per year, relative to S.‐H.I. Ou S.‐H.I. Ou (= 1×) peers Anna Bettini

Countries citing papers authored by S.‐H.I. Ou

Since Specialization

Citations

This map shows the geographic impact of S.‐H.I. Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.‐H.I. Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.‐H.I. Ou more than expected).

Fields of papers citing papers by S.‐H.I. Ou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.‐H.I. Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.‐H.I. Ou. The network helps show where S.‐H.I. Ou may publish in the future.

Co-authorship network of co-authors of S.‐H.I. Ou

This figure shows the co-authorship network connecting the top 25 collaborators of S.‐H.I. Ou. A scholar is included among the top collaborators of S.‐H.I. Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.‐H.I. Ou. S.‐H.I. Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ou, S.‐H.I., et al.. (2023). Aspirin deprescribing in patients on oral anticoagulation for atrial fibrillation or venous thromboembolism: A national survey of clinician practices. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 6(7). 690–700. 2 indexed citations

2.

Gadgeel, Shirish M., Pasi A. Jänne, Alexander I. Spira, et al.. (2023). MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC. Journal of Thoracic Oncology. 18(11). S118–S118. 8 indexed citations

3.

Bauml, Joshua, Santiago Viteri, Anna Minchom, et al.. (2021). FP07.12 Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets. Journal of Thoracic Oncology. 16(3). S208–S209. 28 indexed citations

4.

Rosenzweig, Mark R., Andrew J. Piper‐Vallillo, Paul A. VanderLaan, et al.. (2021). MA02.03 MET-Driven Acquired Resistance (AR) in Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 16(10). S890–S890. 1 indexed citations

5.

Ou, S.‐H.I., Huamao Mark Lin, Sylvie Vincent, et al.. (2021). MA14.01 Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(10). S928–S929. 5 indexed citations

6.

Barlési, Fabrice, Jennifer Moriatis Wolf, Robert C. Doebele, et al.. (2020). 385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Annals of Oncology. 31. S1391–S1392. 3 indexed citations

7.

Bendell, Johanna C., Susanna V. Ulahannan, Julie R. Brahmer, et al.. (2020). Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. European Journal of Cancer. 138. S8–S9. 14 indexed citations

8.

Shaw, A., Yung‐Jue Bang, Donghyeon Kim, et al.. (2019). Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of Oncology. 30(7). 1121–1126. 365 indexed citations breakdown →

9.

DerSarkissian, Maral, Rachel H. Bhak, Huamao Mark Lin, et al.. (2019). P2.01-103 Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology. 14(10). S681–S681. 12 indexed citations

10.

Ou, S.‐H.I., Russell W. Madison, Jin‐Beom Chung, et al.. (2019). Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets. Annals of Oncology. 30. v26–v26. 4 indexed citations

11.

Ou, S.‐H.I., Byoung Chul Cho, D. Kim, et al.. (2018). OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(12). S1047–S1047. 3 indexed citations

12.

Madison, Russell W., Filippo Pietrantonio, Chiara Cremolini, et al.. (2018). Kinase fusions in colorectal cancers: A unique biologic subset. Annals of Oncology. 29. viii152–viii152. 5 indexed citations

13.

Bailey, Michael, Alexa B. Schrock, Samuel J. Klempner, et al.. (2016). Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor. Annals of Oncology. 27. vi493–vi493. 2 indexed citations

14.

Segal, Neil H., S.‐H.I. Ou, Ani Sarkis Balmanoukian, et al.. (2016). Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Annals of Oncology. 27. vi328–vi328. 30 indexed citations

15.

Varga, Andréa, D. Ross Camidge, Lecia V. Sequist, et al.. (2015). 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. European Journal of Cancer. 51. S598–S598. 11 indexed citations

16.

Kim, Kyung-Min, et al.. (2014). Innovative personalized medicine in gastric cancer: time to move forward. Clinical Genetics. 86(1). 37–43. 18 indexed citations

17.

Ou, S.‐H.I., Jason A. Zell, Argyrios Ziogas, & Hoda Anton‐Culver. (2008). Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer. 112(9). 2011–2020. 85 indexed citations

18.

Zell, Jason A., S.‐H.I. Ou, Argyrios Ziogas, & Hoda Anton‐Culver. (2007). Survival improvements for advanced stage nonbronchioloalveolar carcinoma‐type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer. 112(1). 136–143. 23 indexed citations

19.

Raz, Dan J., Jason A. Zell, Anthony N. Karnezis, et al.. (2006). Misclassification of Bronchioloalveolar Carcinoma with Cytologic Diagnosis of Lung Cancer. Journal of Thoracic Oncology. 1(9). 943–948. 10 indexed citations

20.

Raz, Dan J., Jason A. Zell, Anthony N. Karnezis, et al.. (2006). Misclassification of Bronchioloalveolar Carcinoma with Cytologic Diagnosis of Lung Cancer. Journal of Thoracic Oncology. 1(9). 943–948. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact